Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 1;13(1):147.
doi: 10.1186/s13643-024-02554-9.

Biomarkers for personalised prevention of chronic diseases: a common protocol for three rapid scoping reviews

Affiliations

Biomarkers for personalised prevention of chronic diseases: a common protocol for three rapid scoping reviews

E Plans-Beriso et al. Syst Rev. .

Abstract

Introduction: Personalised prevention aims to delay or avoid disease occurrence, progression, and recurrence of disease through the adoption of targeted interventions that consider the individual biological, including genetic data, environmental and behavioural characteristics, as well as the socio-cultural context. This protocol summarises the main features of a rapid scoping review to show the research landscape on biomarkers or a combination of biomarkers that may help to better identify subgroups of individuals with different risks of developing specific diseases in which specific preventive strategies could have an impact on clinical outcomes. This review is part of the "Personalised Prevention Roadmap for the future HEalThcare" (PROPHET) project, which seeks to highlight the gaps in current personalised preventive approaches, in order to develop a Strategic Research and Innovation Agenda for the European Union.

Objective: To systematically map and review the evidence of biomarkers that are available or under development in cancer, cardiovascular and neurodegenerative diseases that are or can be used for personalised prevention in the general population, in clinical or public health settings.

Methods: Three rapid scoping reviews are being conducted in parallel (February-June 2023), based on a common framework with some adjustments to suit each specific condition (cancer, cardiovascular or neurodegenerative diseases). Medline and Embase will be searched to identify publications between 2020 and 2023. To shorten the time frames, 10% of the papers will undergo screening by two reviewers and only English-language papers will be considered. The following information will be extracted by two reviewers from all the publications selected for inclusion: source type, citation details, country, inclusion/exclusion criteria (population, concept, context, type of evidence source), study methods, and key findings relevant to the review question/s. The selection criteria and the extraction sheet will be pre-tested. Relevant biomarkers for risk prediction and stratification will be recorded. Results will be presented graphically using an evidence map.

Inclusion criteria: Population: general adult populations or adults from specific pre-defined high-risk subgroups; concept: all studies focusing on molecular, cellular, physiological, or imaging biomarkers used for individualised primary or secondary prevention of the diseases of interest; context: clinical or public health settings.

Systematic review registration: https://doi.org/10.17605/OSF.IO/7JRWD (OSF registration DOI).

Keywords: Biomarkers; Cancer; Cardiovascular diseases; Chronic diseases; Neoplasm; Neurodegenerative diseases; Personalised prevention; Precision Medicine; Precision prevention.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest in this project.

Similar articles

Cited by

References

    1. Council of European Union. Council conclusions on personalised medicine for patients (2015/C 421/03). Brussels: European Union; 2015 dic. Report No.: (2015/C 421/03). Disponible en: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52015XG121....
    1. Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril. 2018;109(6):952–963. doi: 10.1016/j.fertnstert.2018.05.006. - DOI - PMC - PubMed
    1. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); 2016 [citado 3 de febrero de 2023]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK326791/. - PubMed
    1. Porta M, Greenland S, Hernán M, dos Silva I S, Last JM. International Epidemiological Association, editores. A dictionary of epidemiology. 6. Oxford: Oxford Univ. Press; 2014. p. 343.
    1. PROPHET . Project kick-off meeting. Rome. 2022.

MeSH terms